Loading organizations...
Loading organizations...
Selonterra develops therapeutic approaches for neurodegenerative disorders, particularly those with strong genetic links, such as Alzheimer's disease. The company utilizes human genetics to pinpoint and target underlying biological pathways, aiming to transform treatment paradigms. Its proprietary technologies and drug pipeline address genetic factors, offering precision interventions for these conditions.
Anne Urfer-Buchwalder, PhD, and Roman Urfer, PhD, co-founded Selonterra, serving as President and Chief Executive Officer. They established the company, driven by the insight that many neurodegenerative diseases possess significant genetic components amenable to precise therapeutic targeting. Their biotechnology expertise forms the scientific bedrock and strategic direction of the company.
Selonterra’s therapies are designed for patients afflicted with neurodegenerative conditions, providing new treatment options where current solutions are insufficient. The company envisions pioneering the fight against neurodegeneration by translating genetic discoveries into transformative therapeutics, offering a forward-looking promise for improved patient outcomes in this critical medical area.
Selonterra, Inc. is a San Francisco Bay Area-based biotechnology company developing small molecule therapies for neurodegenerative disorders like Alzheimer's disease (AD), Parkinson's disease, and ALS/FTD.[1][2][3][4][5] It harnesses human genetics, gene regulatory networks, and molecular pathway analysis to identify novel, unexploited targets, focusing on disease-modifying drugs that address root causes such as APOE4-induced dysfunction, LRRK2 x α-synuclein interactions, and C9orf72 mechanisms.[2][4][5] The company serves patients with these genetically linked conditions through a precision-medicine approach, enabling targeted clinical studies and improved outcomes; its pipeline features preclinical chemical drugs, with lead compounds restoring synaptic deficits and poised for lead optimization and IND-enabling studies.[4][5] Backed by venture capital, Selonterra collaborates globally with specialized firms like Axxam for drug discovery, demonstrating early momentum via high-throughput screening successes.[3][4]
Selonterra was founded by Roman Urfer, PhD (CEO) and Anne Urfer-Buchwalder, PhD (President), both seasoned biotech executives with decades of experience.[2][4] Roman Urfer brings R&D and business expertise from Novartis, Genentech, and startups, including discovery of stroke recovery molecules, antibodies for inflammation, and neurotrophic factors; he's named on 20 patents and led a $31M financing round.[2] Anne Urfer-Buchwalder started at Transgene SA (leading to patents), worked at Sandoz/Novartis, University of Basle, City of Hope, and Spectra-Biomedical (acquired by GSK), and ran Migraine Therapeutics before co-founding Selonterra.[2] The idea emerged from their recognition of strong human genetic links in neurodegeneration, aiming to exploit untargeted gene expression networks for small molecule drugs; early traction includes VC funding, a 2020 drug discovery collaboration with Axxam on AD targets, and building a global collaborator network.[2][3][4]
Selonterra rides the genetics-driven biotech wave in neurodegeneration, where GWAS and multi-omics reveal actionable targets amid failures of amyloid/tau-focused AD drugs.[2][4] Timing aligns with surging demand for precision therapies—neurodegenerative cases are projected to triple by 2050—fueled by advances in gene editing, AI pathway analysis, and small molecule screening.[1][3] Market forces like aging populations, VC interest in CNS (despite risks), and regulatory pushes for biomarkers favor its approach, differentiating from big pharma's broad trials.[3][5] It influences the ecosystem by validating novel targets, partnering with CROs like Axxam, and pioneering small molecules for genetically stratified patients, potentially accelerating industry shifts to root-cause modulation.[2][3][4]
Selonterra's near-term path centers on lead optimization for AD/Parkinson's programs, advancing to IND studies with partners, while expanding its genetics platform across pipeline assets.[3][4][5] Trends like AI-enhanced genetics, combination therapies, and precision neurology will propel it, especially if preclinical data de-risks targets. Its influence could grow via milestones like first-in-human trials or Big Pharma licensing, transforming it from VC-funded pioneer to ecosystem leader—echoing its mission to redefine neurodegeneration treatment through untapped genetic insights.[2][4]